Efficacy, tolerability, and accessibility of tapinarof cream 1% in the treatment of atopic dermatitis: Case series

Summary: Abstract Body: Tapinarof cream 1% once daily (QD) is novel topical treatment with a unique mechanism of action, recently FDA-approved in 2022 for plaque psoriasis in adults and pending for FDA-approved indication to treat atopic dermatitis in March 2024. The objective of the study was to assess efficacy, tolerability, and accessibility of tapinarof in treating atopic dermatitis. This case series follows 14 patients across an electronic medical record platform, DermCafe, for demographic (age, gender, ethnicity, phototype), severity and spread of atopic dermatitis, and adverse effects. The primary outcome is clinical improvement within interval of treatment and efficacy based on standardized initial and current patient oriented eczema measure (poem) score. Secondary outcome includes financial accessibility including insurance coverage and cost. The sample size limited to 14 patients within Los Angeles, California. Tapinarof cream 1% once daily shows significant clinical improvement given 13 of 14 patients exhibit significant improvement. Joy Xu¹, Mitchell Hanson², Alyssa Wu³, Sia Mehta⁷, Sophia Salazar⁴, Aashita Doshi⁵, Annie Liu⁶ 1. University of California Los Angeles David Geffen School of Medicine, Los Angeles, CA, United States. 2. Augusta University, Augusta, GA, United States. 3. Western University, London, ON, Canada. 4. University of Toronto, Toronto, ON, Canada. 5. The University of Texas at Dallas School of Behavioral and Brain Sciences, Richardson, TX, United States. 6. DermCafe, Los Angeles, CA, United States. 7. Providence High School, Charlotte, NC, United States. Clinical Research: Interventional Research